Sanofi
Human Cytomegalovirus Immunogenic Composition
Last updated:
Abstract:
The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1-inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.
Status:
Application
Type:
Utility
Filling date:
11 Sep 2018
Issue date:
3 Sep 2020